Extended B cell phenotype in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional study

Clinical and Experimental Immunology

Volumn 184, Issue 2, 2016, Pages 237-247

  Mensah, F ^a   Bansal, A ^b   Berkovitz, S ^c   Sharma, A ^a   Reddy, V ^a   Leandro, M J ^a   Cambridge, G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b EPSOM AND ST HELIER UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

B cells; chronic fatigue syndrome; flow cytometry; human; myalgic encephalomyelitis

Indexed keywords

B CELL ACTIVATING FACTOR; CD19 ANTIGEN; CD24 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; CD5 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CHRONIC FATIGUE SYNDROME; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DISEASE DURATION; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; PLASMABLAST; PRE B LYMPHOCYTE; PRIORITY JOURNAL; SJOEGREN SYNDROME;

EID: 84983260367     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12749     Document Type: Article

References (73)

1. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994; 121:953–9.
2. Carruthers BM, van de Sande MI, De Meirleir KL et al. Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med 2011; 270:327–38.
3. Brurberg KG, Fonhus MS, Larun L, Flottorp S, Malterud K. Case definitions for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): a systematic review. BMJ Open 2014; 4:e003973
4. Ablashi DV. Viral studies of chronic fatigue syndrome. Clin Infect Dis 1994; 18:S130–1.
5. Levy JA. Viral studies of chronic fatigue syndrome. Clin Infect Dis 1994; 18 (Suppl. 1):S117–20.
6. Loebel M, Strohschein K, Giannini C et al. Deficient EBV-specific B- and T cell response in patients with chronic fatigue syndrome. PLOS ONE 2014; 9:e85387.
7. Bansal AS, Bradley AS, Bishop KN, Kiani-Alikhan S, Ford B. Chronic fatigue syndrome, the immune system and viral infection. Brain Behav Immun 2012; 26:24–31.
8. Chapenko S, Krumina A, Logina I et al. Association of active human herpesvirus-6, −7 and parvovirus b19 infection with clinical outcomes in patients with myalgic encephalomyelitis/chronic fatigue syndrome. Adv Virol 2012; 2012:205085.
9. Agliari E, Barra A, Vidal KG, Guerra F. Can persistent Epstein–Barr virus infection induce chronic fatigue syndrome as a Pavlov reflex of the immune response? J Biol Dyn 2012; 6:740–62.
10. Brenu EW, van Driel ML, Staines DR et al. Immunological abnormalities as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med 2011; 9:81.
11. Brenu EW, Huth TK, Hardcastle SL et al. Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis. Int Immunol 2014; 26:233–42.
12. Fletcher MA, Zeng XR, Maher K et al. Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26. PLOS ONE 2010; 5:e10817.
13. Maher KJ, Klimas NG, Fletcher MA. Chronic fatigue syndrome is associated with diminished intracellular perforin. Clin Exp Immunol 2005; 142:505–11.
14. Odom CI, Gaston DC, Markert JM, Cassady KA. Human herpesviridae methods of natural killer cell evasion. Adv Virol 2012; 2012:359869.
15. Curriu M, Carrillo J, Massanella M et al. Screening NK-, B- and T cell phenotype and function in patients suffering from chronic fatigue syndrome. J Transl Med 2013; 11:68.
16. Pasi A, Bozzini S, Carlo-Stella N et al. Excess of activating killer cell immunoglobulinlike receptors and lack of HLA-Bw4 ligands: a two edged weapon in chronic fatigue syndrome. Mol Med Rep 2011; 4:535–40.
17. Fletcher MA, Zeng XR, Barnes Z, Levis S, Klimas NG. Plasma cytokines in women with chronic fatigue syndrome. J Transl Med 2009; 7:96.
18. Tomoda A, Joudoi T, Rabab el M, Matsumoto T, Park TH, Miike T. Cytokine production and modulation: comparison of patients with chronic fatigue syndrome and normal controls. Psychiatry Res 2005; 134:101–4.
19. Devanur LD, Kerr JR. Chronic fatigue syndrome. J Clin Virol 2006; 37:139–50.
20. Hornig M, Gottschalk G, Peterson DL et al. Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Mol Psychiatry. 2016; 21:261–9.
21. Hornig M, Montoya JG, Klimas NG et al. Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci Adv 2015; 1:e1400121.
22. Peterson D, Brenu EW, Gottschalk G et al. Cytokines in the cerebrospinal fluids of patients with chronic fatigue syndrome/myalgic encephalomyelitis. Mediators Inflamm 2015; 2015:929720.
23. Hickie I, Davenport T, Wakefield D et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ 2006; 333:575.
24. Broderick G, Katz BZ, Fernandes H et al. Cytokine expression profiles of immune imbalance in post-mononucleosis chronic fatigue. J Transl Med 2012; 10:191.
25. Pizzichini MM, Pizzichini E, Efthimiadis A et al. Asthma and natural colds. Inflammatory indices in induced sputum: a feasibility study. Am J Respir Crit Care Med 1998; 158:1178–84.
26. Chanan-Khan AA, Chitta K, Ersing N et al. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol 2011; 155:457–67.
27. Torchinsky MB, Blander JM. T helper 17 cells: discovery, function, and physiological trigger. Cell Mol Life Sci 2010; 67:1407–21.
28. Fluge O, Bruland O, Risa K et al. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLOS ONE 2011; 6:e26358.
29. Fluge O, Risa K, Lunde S et al. B-lymphocyte depletion in Myalgic Encephalopathy/Chronic Fatigue Syndrome. An open-label phase II study with rituximab maintenance treatment. PLOS ONE 2015; 10:e0129898.
30. Maes M, Mihaylova I, Kubera M, Leunis JC, Twisk FN, Geffard M. IgM-mediated autoimmune responses directed against anchorage epitopes are greater in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) than in major depression. Metab Brain Dis 2012; 27:415–23.
31. Konstantinov K, von Mikecz A, Buchwald D, Jones J, Gerace L, Tan EM. Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome. J Clin Invest 1996; 98:1888–96.
32. von Mikecz A, Konstantinov K, Buchwald DS, Gerace L, Tan EM. High frequency of autoantibodies to insoluble cellular antigens in patients with chronic fatigue syndrome. Arthritis Rheum 1997; 40:295–305.
33. Tanaka S, Kuratsune H, Hidaka Y et al. Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome. Int J Mol Med 2003; 12:225–30.
34. Loebel M, Grabowski P, Heidecke H et al. Antibodies to beta adrenergic and muscarinic cholinergic receptors in patients with chronic fatigue syndrome. Brain Behav Immun 2016;52:32–9.
35. Gupta S, Vayuvegula B. A comprehensive immunological analysis in chronic fatigue syndrome. Scand J Immunol 1991; 33:319–27.
36. Hassan IS, Bannister BA, Akbar A, Weir W, Bofill M. A study of the immunology of the chronic fatigue syndrome: correlation of immunologic parameters to health dysfunction. Clin Immunol Immunopathol 1998; 87:60–7.
37. Straus SE, Fritz S, Dale JK, Gould B, Strober W. Lymphocyte phenotype and function in the chronic fatigue syndrome. J Clin Immunol 1993; 13:30–40.
38. Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990; 28:1403–10.
39. Tirelli U, Marotta G, Improta S, Pinto A. Immunological abnormalities in patients with chronic fatigue syndrome. Scand J Immunol 1994; 40:601–8.
40. Bradley AS, Ford B, Bansal AS. Altered functional B cell subset populations in patients with chronic fatigue syndrome compared to healthy controls. Clin Exp Immunol 2013; 172:73–80.
41. Kaminski DA, Wei C, Qian Y, Rosenberg AF, Sanz I. Advances in human B cell phenotypic profiling. Front Immunol 2012; 3:302.
42. Bohnhorst JO, Bjorgan MB, Thoen JE, Natvig JB, Thompson KM. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome. J Immunol 2001; 167:3610–8.
43. Vlkova M, Fronkova E, Kanderova V et al. Characterization of lymphocyte subsets in patients with common variable immunodeficiency reveals subsets of naive human B cells marked by CD24 expression. J Immunol 2010; 185:6431–8.
44. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:613–20.
45. Sanz I. Rationale for B cell targeting in SLE. Semin Immunopathol 2014; 36:365–75.
46. Shi Y, Agematsu K, Ochs HD, Sugane K. Functional analysis of human memory B cell subpopulations: IgD+CD27+ B cells are crucial in secondary immune response by producing high affinity IgM. Clin Immunol 2003; 108:128–37.
47. Darce JR, Arendt BK, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 2007; 179:7276–86.
48. Tedder TF, Inaoki M, Sato S. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 1997; 6:107–18.
49. Reljic R, Cosentino G, Gould HJ. Function of CD23 in the response of human B cells to antigen. Eur J Immunol 1997; 27:572–5.
50. Lee J, Kuchen S, Fischer R, Chang S, Lipsky PE. Identification and characterization of a human CD5+ pre-naive B cell population. J Immunol 2009; 182:4116–26.
51. Cherukuri A, Cheng PC, Pierce SK. The role of the CD19/CD21 complex in B cell processing and presentation of complement-tagged antigens. J Immunol 2001; 167:163–72.
52. Chang CM, Warren JL, Engels EA. Chronic fatigue syndrome and subsequent risk of cancer among elderly US adults. Cancer 2012; 118:5929–36.
53. Zhang H, Li P, Wu D et al. Serum IgG subclasses in autoimmune diseases. Medicine (Baltimore) 2015; 94:e387.
54. Popovic K1, Brauner S, Ek M, Wahren-Herlenius M, Nyberg F. Fine specificity of the Ro/SSA autoantibody response in relation to serological and clinical findings in 96 patients with self-reported cutaneous symptoms induced by the sun. Lupus 2007; 16:10–7.
55. Blanco F, Kalsi J, Ravirajan CT, Speight P, Bradwell AR, Isenberg DA. IgG subclasses in systemic lupus erythematosus and other autoimmune rheumatic diseases. Lupus 1992; 1:391–9.
56. Reddy V, Croca S, Gerona D et al. Serum rituximab levels and efficiency of B cell depletion: differences between patients with rheumatoid arthritis and systemic lupus erythematosus. Rheumatology (Oxf) 2013; 52:951–2.
57. Nowak RJ, Dicapua DB, Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord 2011; 4:259–66.
58. Natelson BH, Haghighi MH, Ponzio NM. Evidence for the presence of immune dysfunction in chronic fatigue syndrome. Clin Diagn Lab Immunol 2002; 9:747–52.
59. Fang X, Zheng P, Tang J, Liu Y. CD24: from A to Z. Cell Mol Immunol 2010; 7:100–3.
60. Lu L, Chappel MS, Humphries RK, Osmond DG. Regulation of cell survival during B lymphopoiesis: increased pre-B cell apoptosis in CD24-transgenic mouse bone marrow. Eur J Immunol 2000; 30:2686–91.
61. Nielsen PJ, Lorenz B, Muller AM et al. Altered erythrocytes and a leaky block in B cell development in CD24/HSA-deficient mice. Blood 1997; 89:1058–67.
62. Wenger RH, Kopf M, Nitschke L, Lamers MC, Kohler G, Nielsen PJ. B cell maturation in chimaeric mice deficient for the heat stable antigen (HSA/mouse CD24). Transgenic Res 1995; 4:173–83.
63. Zhou Q, Rammohan K, Lin S et al. CD24 is a genetic modifier for risk and progression of multiple sclerosis. Proc Natl Acad Sci USA 2003; 100:15041–6.
64. Otaegui D, Saenz A, Camano P et al. CD24 V/V is an allele associated with the risk of developing multiple sclerosis in the Spanish population. Mult Scler 2006; 12:511–4.
65. Sanchez E, Abelson AK, Sabio JM et al. Association of a CD24 gene polymorphism with susceptibility to systemic lupus erythematosus. Arthritis Rheum 2007; 56:3080–6.
66. Sanchez E, Fernandez-Gutierrez B, Gonzalez-Gay MA et al. Investigating the role of CD24 gene polymorphisms in rheumatoid arthritis. Ann Rheum Dis 2008; 67:1197–8.
67. Rueda B, Miranda-Filloy JA, Martin J, Gonzalez-Gay MA. Association of CD24 gene polymorphisms with susceptibility to biopsy-proven giant cell arteritis. J Rheumatol 2008; 35:850–4.
68. Wang L, Lin S, Rammohan KW et al. A dinucleotide deletion in CD24 confers protection against autoimmune diseases. PLOS Genet 2007; 3:e49.
69. Suzuki T, Kiyokawa N, Taguchi T, Sekino T, Katagiri YU, Fujimoto J. CD24 induces apoptosis in human B cells via the glycolipid-enriched membrane domains/rafts-mediated signaling system. J Immunol 2001; 166:5567–77.
70. Das A, Xu H, Wang X, Yau CL, Veazey RS, Pahar B. Double-positive CD21+CD27+ B cells are highly proliferating memory cells and their distribution differs in mucosal and peripheral tissues. PLOS ONE 2011; 6:e16524.
71. Myhill S, Booth NE, McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med 2009; 2:1–16.
72. Booth NE, Myhill S, McLaren-Howard J. Mitochondrial dysfunction and the pathophysiology of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Int J Clin Exp Med 2012; 5:208–20.
73. Morris G, Maes M. Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. Metab Brain Dis 2014; 29:19–36.